DUX4 and facioscapulohumeral muscular dystrophy: Although these will likely prove very useful, we propose that having the ability to directly measure DUX4 expression would be optimal for FSHD therapeutic strategies that are aimed at reducing DUX4 levels, such as an RNAi-based gene therapy we are working to translate (Wallace et al. 2012, 2018).